Page last updated: 2024-12-10

adrafinil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID3033226
CHEMBL ID93077
CHEBI ID135200
SCHEMBL ID49334
MeSH IDM0077767

Synonyms (53)

Synonym
CHEMBL93077
olmifon
crl-40028
adrafinil ,
acetohydroxamic acid, 2-((diphenylmethyl)sulfinyl)-
acetamide, 2-((diphenylmethyl)sulfinyl)-n-hydroxy-
adrafinil [inn]
brn 1990030
einecs 264-303-1
adrafinilum [inn-latin]
2-((diphenylmethyl)sulfinyl)acetohydroxamsaeure
2-((diphenylmethyl)sulfinyl)-n-hydroxyacetamide
2-((diphenylmethyl)sulfinyl)acetohydroxamic acid
2-(benzhydrylsulfinyl)acetohydroxamic acid
crl 40028
adrafinil (inn)
63547-13-7
olmifon (tn)
D07348
adrafinil, >=98% (hplc), solid
NCGC00165714-01
NCGC00165714-02
CHEBI:135200
2-benzhydrylsulfinyl-n-hydroxyacetamide
dtxsid4046498 ,
cas-63547-13-7
dtxcid2026498
tox21_112258
AKOS015994532
unii-bi81z4542g
bi81z4542g ,
adrafinilum
2-[(diphenylmethyl)sulfinyl]-n-hydroxyacetamide
2-[(diphenylmethyl)sulfinyl]acetohydroxamic acid
AB07489
adrafinil [mi]
adrafinil [nflis-drug]
adrafinil [who-dd]
adrafinil [mart.]
S5224
acetamide, 2-[(s)-(diphenylmethyl)sulfinyl]-n-hydroxy-
HY-17549
SCHEMBL49334
AF-0056
W-104904
mfcd00865357
EX-A733
F17382
2-(benzhydrylsulfinyl)-n-hydroxyacetamide
Q366482
2-(benzhydrylsulphinyl)acetohydroxamic acid
HMS3886M15
CCG-267371

Research Excerpts

Actions

ExcerptReferenceRelevance
"Adrafinil caused an increase in locomotor activity at the three highest doses at both the 2- and 10-h intervals and during both the first (days 1 and 5) and second treatment week (days 9 and 13)."( Behavioral activating effects of adrafinil in aged canines.
Callahan, H; Gruet, P; Milgram, NW; Muggenburg, BA; Murphey, HL; Schneider, M; Siwak, CT; Woehrlé, F, 2000
)
1.31

Treatment

Treatment with adrafinil produced significant improvement in learning, as indicated by a decrease in both errors and trials to criterion. Treatment may improve the quality of life of aged dogs by increasing exploratory behavior and alertness.

ExcerptReferenceRelevance
"Treatment with adrafinil produced significant improvement in learning, as indicated by a decrease in both errors and trials to criterion."( Oral administration of adrafinil improves discrimination learning in aged beagle dogs.
Atkinson, P; Callahan, H; Gruet, P; Milgram, NW; Siwak, CT; Woehrlé, F, 2000
)
0.96
"Treatment with adrafinil resulted in a significant increase in locomotion in each of the open-field tests and an increase in locomotion in the home cage. "( Comparison of the effects of adrafinil, propentofylline, and nicergoline on behavior in aged dogs.
Gruet, P; Milgram, NW; Muggenburg, BA; Murphey, HL; Siwak, CT; Woehrlé, F, 2000
)
0.95
"Treatment with adrafinil may improve the quality of life of aged dogs by increasing exploratory behavior and alertness."( Comparison of the effects of adrafinil, propentofylline, and nicergoline on behavior in aged dogs.
Gruet, P; Milgram, NW; Muggenburg, BA; Murphey, HL; Siwak, CT; Woehrlé, F, 2000
)
0.95

Pharmacokinetics

ExcerptReferenceRelevance
" The method was successfully applied to pharmacokinetic studies of adrafinil after an oral administration to rats."( LC-ESI-MS determination and pharmacokinetics of adrafinil in rats.
Agawane, SB; Rao, RN; Shinde, DD; Talluri, MV, 2008
)
0.84

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
diarylmethaneAny compound containing two aryl groups connected by a single C atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency3.34910.000221.22318,912.5098AID743042
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency2.86950.005612.367736.1254AID624032
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency35.48130.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID227701Anticonvulsant activity; NC denotes that compound is not classified2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (21.43)18.7374
1990's3 (10.71)18.2507
2000's12 (42.86)29.6817
2010's6 (21.43)24.3611
2020's1 (3.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 48.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index48.47 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index4.50 (4.65)
Search Engine Demand Index116.30 (26.88)
Search Engine Supply Index3.15 (0.95)

This Compound (48.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (6.45%)5.53%
Reviews0 (0.00%)6.00%
Case Studies2 (6.45%)4.05%
Observational0 (0.00%)0.25%
Other27 (87.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]